Acute Myeloid Leukemia (AML) is one of the most common acute leukemia in adults and still with a large unmet need for new therapies. The 5-year overall survival (OS) rate of AML is ~30%, and standard treatment regimens have changed remarkably little since the 1970s. In particular, antibody drug conjugates (ADCs) have fallen short of […]
